





RESEARCH ARTICLE

Early detection of macrovascular complications in type 2 diabetes mellitus in Medan, North Sumatera, Indonesia: A cross-sectional study [version 1; peer review: 2 approved]

Rina Amelia¹, Juliandi Harahap ¹, Yuki Yunanda¹, Hendri Wijaya²,
Isti Ilmiati Fujiati¹, Zulham Yamamoto ³

¹Department of Community Medicine/Public Health, Faculty of Medicine, Universitas Sumatera Utara, Medan, North Sumatera, 20155, Indonesia

²Department of Pediatrics, Faculty of Medicine, Universitas Sumatera Utara, Medan, North Sumatera, 20155, Indonesia

³Department of Histology, Faculty of Medicine, Universitas Sumatera Utara, Medan, North Sumatera, 20155, Indonesia

V1 First published: 16 Aug 2021, 10:808
<https://doi.org/10.12688/f1000research.54649.1>
Latest published: 16 Aug 2021, 10:808
<https://doi.org/10.12688/f1000research.54649.1>

Abstract

Background: Macrovascular complications occur very frequently in patients with type 2 diabetes mellitus (T2DM) with a high mortality rate, due to the development of cardiovascular disease (CVD), such as stroke, atherosclerosis acceleration, and atrial fibrillation. T2DM is a significant risk factor for CVD and has become the leading cause of death. The purpose of this study was to detect the early risk of macrovascular complications by using the ankle brachial index (ABI) as a marker.

Methods: This study was an analytic study with a cross-sectional approach. The study population was patients with T2DM from several primary health care centers in Medan. In total, 89 subjects who met the inclusion and exclusion criteria were recruited with consecutive sampling. ABI was determined as the ratio of systolic blood pressure in the brachial artery to the posterior tibial artery after the subjects had been relaxed and felt comfortable in a supine position. Examination of vitamin D and lipid profile was derived from examination of venous blood. Data were processed using SPSS and analyzed with one-way ANOVA.

Results: The study found that there was a relationship between LDL-C, triglyceride, and vitamin D (25OH-D) based on the ABI ($p > 0.05$).

Conclusions: ABI can be used for an early detection of macrovascular complications. Apart from being easy to perform, ABI was non-invasive. Some other risk factors that can also be used to assess complications and have relationships with ABI were LDL-C, triglyceride, and vitamin D (25OH-D). Complications in T2DM patients can be prevented with reasonable blood sugar control and lifestyle changes. Education and motivation need to be given to patients so that they become more independent in controlling their disease and

Open Peer Review

Reviewer Status  

Invited Reviewers

1

2

version 1



16 Aug 2021



report



report

1. **Mohd Adzim Khalili Rohin** , Sultan Zainal Abidin University, Kuala Terengganu, Malaysia
2. **Hari Kusnanto** , Gadjah Mada University, Yogyakarta, Indonesia

Any reports and responses or comments on the article can be found at the end of the article.

improving their quality of life.

Keywords

macrovascular complications, ankle brachial index, hydroxy vitamin D, LDL-C, triglyceride, HDL-C

Corresponding author: Rina Amelia (rina2@usu.ac.id)

Author roles: **Amelia R:** Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Methodology, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Harahap J:** Formal Analysis, Investigation, Methodology, Software, Supervision, Validation; **Yunanda Y:** Formal Analysis, Investigation, Resources, Software, Validation, Visualization; **Wijaya H:** Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Resources, Software, Supervision, Writing – Original Draft Preparation; **Fujiati II:** Conceptualization, Data Curation, Investigation, Project Administration, Resources, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Yamamoto Z:** Data Curation, Formal Analysis, Investigation, Methodology, Software, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The authors would like to acknowledge The Ministry of Research and Technology/ National Research and Innovation Agency for the 2020 Fiscal Year by the Research Contract Amendment No. 11 / AMD / E1 / KP. PTNBH / 2020, dated 11 May 2020
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2021 Amelia R *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Amelia R, Harahap J, Yunanda Y *et al.* **Early detection of macrovascular complications in type 2 diabetes mellitus in Medan, North Sumatera, Indonesia: A cross-sectional study [version 1; peer review: 2 approved]** F1000Research 2021, 10:808 <https://doi.org/10.12688/f1000research.54649.1>

First published: 16 Aug 2021, 10:808 <https://doi.org/10.12688/f1000research.54649.1>

Introduction

Patients with type 2 diabetes mellitus (T2DM) are at risks of short- and long-term complications. Long-term complications include macrovascular and microvascular diseases.¹ Macrovascular complications occur very frequently in patients with T2DM with a high mortality rate, due to the development of cardiovascular disease (CVD) such as stroke, atherosclerosis acceleration, and atrial fibrillation. T2DM is a significant risk factor for CVD and has become the leading cause of death, whereby almost 50% of the total deaths are due to this disease.¹ It is estimated that the mortality rate of CVD increases almost threefold in T2DM.² Besides CVD complication, peripheral arterial disease (PAD) has also become a serious condition of macrovascular complications. PAD is characterized by narrowing peripheral arteries due to atherosclerosis, and it generally occurs in the leg arteries. Many patients with T2DM are suffering from PAD, and as this disease is non-symptomatic, it is undetected. PAD is one of the T2DM complications associated with CVD.^{3–6} Atherosclerosis is the most common and important cause of PAD. Dyslipidemia, smoking, hypertension, and T2DM are also known as risk factors for PAD, CVD and coronary artery disease.⁷ Ankle brachial index (ABI) is a non-invasive tool for detecting vascular status and for measuring lower leg arteries versus upper leg arterial health status.⁸ ABI is the ratio between the lower limb (ankle) systolic blood pressure and the upper limb (upper arm) systolic blood pressure. ABI reflects vascular resistance, which explains the main factors: the blood vessel diameter, which can be narrowed either from internal factors (plaque and intimal tearing) or from external factors, such as compression by soft tissue.⁹ ABI examination is a non-invasive gold standard measurement to detect PAD; consequently, the examination is highly recommended for patients with T2DM and others at risk of suffering from PAD. An early detection can reduce the risk of more severe complications, such as neuropathy and CVD disorders.⁵ The purpose of this study was to detect the early risk of macrovascular complications by using the ABI as a marker.

Methods

Study design

This was an analytical study with a cross-sectional approach. The study had the ethical approval from the Research Ethics Commission of Universitas Sumatera Utara (Approval number No:280/KEP/USU/2020).

Population and samples

The study population consisted of patients with T2DM in Medan. The sample size was determined using one-proportion hypothesis test with an accuracy of 10% and a significance of 95%.¹⁰ A total of 89 subjects that met the inclusion and exclusion criteria were recruited with consecutive sampling technique. Patients who participated in this study were recruited from three primary health services in Medan (Medan Tuntungan, Medan Selayang, and Medan Belawan. The research process lasted for six months, starting from determining the patient, taking blood and laboratory examinations to completion.

Patients who regularly visited the primary health service and were willing to participate were included in this study. Patients with a history of vascular disorders before they had diabetes, leg trauma, stroke, and those with clotting blood disorders were excluded from this study. During the recruitment, selected subjects were firstly, explained about this study, the examination procedure, the process of taking blood, and explaining the discomfort experienced by the patient in the process. Next, if they agreed to join the study after they had understood the explanation about the study protocol, they were asked to sign a consent statement.

Data collection

Most of the data collection was done between 18th Aug 2020 and 10th September 2020. ELISA examination, which had to be carried out in the integrated laboratory of the Faculty of Medicine of Universitas Sumatera Utara, was delayed, and could only be carried out on 10th November 2020 due to the pandemic situation that caused limited active laboratory staff with limited working hours. By early December 2020, all data had been collected and then analyzed. ABI was determined as the ratio of systolic blood pressure in the brachial artery to the posterior tibial artery. Blood pressure was measured after the subject felt relaxed and comfortable for 5 minutes in a supine position. Blood pressure was measured by using a mercury sphygmomanometer (ReisterTM). For measuring the blood pressure of the brachial artery, the cuff was placed at the upper arm. The systolic pressure was considered as the first occurrence of rhythmic sounds heard with stethoscope placed on the antecubital fossa. For the posterior tibial blood pressure, the cuff was placed at the ankle, the systolic pressure was considered as the first pulse was palpable on the dorsum pedis during the cuff deflation. ABI lower than 0.90 was considered abnormal, which was then classified into 0.41–0.90 as a mild to moderate decrease in blood flow, while <0.40 as a severe decrease in blood flow.^{11,12}

Hydroxyvitamin D (25OH-D) level and lipid profile (total cholesterol, HDL-C, LDL-C, and triglyceride level) were analyzed from the venous blood samples (5 ml) drawn after 10 hours fasting. Hydroxyvitamin D (25OH-D) were measured through enzyme-linked immunosorbent assay (ELISA) with human vitamin D ELISA kit (Cat. No E1543Hu,

Brand Bioassay TL). Serum for lipid profile was processed by and Auto Analyzer (Indiko Thermo Scientific™) and the total cholesterol (TC) level was measured using cholesterol oxidase method, HDL-C and LDL-C levels analyzed by enzymatic colorimetric method,¹³ and triglyceride (TG) level was measured using the GPO-Trinded method.¹⁴

Determination of the patient's nutritional status was done by using the Body Mass Index (BMI), which is defined as body weight in kilograms divided by the square of body height in meters (kg/m²), which is then adjusted to the World Health Organization classification.¹⁵

Data analysis

The data was analyzed with SPSS 22 for Windows and then shown in tables. The data under consideration was complete data; any incomplete data was deleted. We included all participants who satisfied the inclusion criteria until the minimal number of samples was reached.

The Kolmogorov Smirnov test ($p > 0.05$) was used to estimate the average of the normal distribution of the sample data. The normality test findings were utilized in the following analysis: parametric analysis was done if the distribution was normal; otherwise, non-parametric analysis was used. To show how ABI influenced average age, diabetes duration, blood pressure, total cholesterol, HDL-C, LDL-C, TG, and vitamin D (25OH-D) ($p < 0.05$), a one-way ANOVA was used. The method was then followed by least significant difference or Bonferroni testing if a significant result was obtained ($p < 0.05$).

Results

Most patients were female (69 subjects, 77.5%), and from the age group of 46–55 years (37 subjects, 41.6%). Normal nutritional status was noted in 44 subjects (49.4%). Based on the duration of illness, more than half of the subjects (47 subjects, 52.8%) had T2DM for 1–5 years (Table 1).

Table 2 shows that 34 (38.2%) patients were in the borderline PAD category, meaning that the peripheral circulation had begun to be disrupted but not included as having PAD. In contrast, 26 patients (29.2%) had mild PAD.

Table 3 indicated that there were differences in average levels of LDL-C, TG and vitamin D (25OH-D), based on ABI ($p < 0.05$). However, age, duration of illness, blood pressure, TC, and HDL-C did not show this difference ($p > 0.05$). It was concluded that there was a relationship between LDL-C, TG, and vitamin D (25OH-D) based on ABI classification.

Table 1. Basic characteristics of type 2 diabetes mellitus patients.

Characteristics	Number of patients (n = 89)	Percentage (%)
Gender		
Male	20	22.5
Female	69	77.5
Age, years (mean, SD)	55.2	8.9
Age group		
<36 years	1	1.1
36-45 years	12	13.5
46-55 years	37	41.6
56-65 years	29	32.6
>65 years	10	11.2
Nutritional Status (BMI = kg/m ²)		
Underweight (<18.5)	3	3.4
Normal (18.5-24.9)	44	49.4
Overweight (25.0-29.9)	25	28.1
Grade 1 Obese (30.0-34.9)	14	15.7
Grade 2 Obese (35.0-39.9)	3	3.4
Duration of illness, years (mean, SD)	4.4	4.3
<1 year	18	20.2
1-5 years	47	52.8
6-10 years	16	18.0
>10 years	8	9.0

Table 2. Ankle brachial index (ABI) classification in patients with type 2 diabetes mellitus.

ABI classification	Number of patients (n = 89)	Percentage (%)
Normal	29	32.6
Borderline	34	38.2
Mild PAD	26	29.2

Table 3. Ankle brachial index (ABI) classification in patients with type 2 diabetes mellitus.

Variables	ABI Classification						p
	Normal		Borderline		Mild peripheral arterial disease		
	Mean	SD	Mean	SD	Mean	SD	
Age	55.6	9.0	53.2	4.8	49.0	12.0	0.225
Duration of diabetes	4.6	4.4	3.3	3.6	2.3	2.3	0.405
Blood Pressure (systole) (mmHg)	149.5	21.1	167.5	31.9	156.7	16.3	0.353
Total cholesterol (mg/dl)	219.5	42.1	220	40.1	249.3	49.2	0.950
HDL-C (mg/dl)	46.6	11.8	44.7	9.2	53.3	12.8	0.750
LDL-C (mg/dl)	126.6	35.8	124.0	30.2	150.0	13.0	0.0325*
Triglycerides (mg/dl)	242.7	127.1	253.8	67.0	350.3	162.9	0.0406*
Vitamin D (25OH-D) (ng/ml)	16.5	0,26	16.4	0,26	25.0	0,21	0.0393*

Discussion

Diabetes with vascular inflammation has become a risk factor for atherothrombotic diseases, such as PAD.¹⁶ A low ABI value reflects atherosclerosis in the vessel wall, resulting in a decrease of perfusion and arterial circulation to the distal extremities.¹⁷ This reduction in perfusion is usually characterized by loss of peripheral pulses, intermittent claudication, and complicated infection of the legs.¹⁸ The pathogenesis of atherosclerosis in PAD is the same as that of the coronary arteries. The lesion in the segment creates stenosis or occlusion that usually takes place in the large or medium-sized vessels. The development of these lesions become atherosclerotic plaques with calcium build-up, thin tunica media, destruction of muscle and elastic fibers, and fragmentation of the elastic internal lamina; and thrombus consisting of platelets and fibrin may happen.¹⁹

Hypertension and diabetes increase the risk of the development of macrovascular and microvascular complications.^{7,20} According to a study by Hiramoto (2014), after 30 months of observation, the ABI value decreased in patients with T2DM by 20.7%, with 5% of the patients showing PAD symptoms.¹⁹ The factors causing the decrease in ABI were influenced by age, gender, high HbA1c, high serum creatinine, high LDL-C, and retinopathy.²¹

Dyslipidemia is a metabolic disorder associated with diabetes. It is characterized by a spectrum of quantitative and qualitative changes in lipids and lipoproteins, including hypertriglyceridemia, decreased concentrations of high-cholesterol lipoprotein (HDL), and elevated LDL.²² Various studies have proven that the risk factors for cardiovascular disease and death from coronary heart disease are directly related to the concentration of cholesterol in the blood.²³ Hypercholesterolemia can directly cause endothelial dysfunction through the production of reactive oxygen species, which converts low-density lipoprotein (LDL) into oxidized low-density lipoprotein (ox-LDL).²⁴ LDL-C and TG are markers that have been used to assess the occurrence of atherosclerosis (atherogenic dyslipidemia).^{25,26} Atherogenic index of plasma, on the other hand, is an instrument that has been used to assess the occurrence of atherosclerosis by using TG level as a marker.^{27,28} Ultimately, small dense LDL-C leads to an increased risk for the development of CVD.²⁹⁻³¹

This study indicated that there was no relationship between the length of illness and age with ABI. The results were not in line with other studies that showed that age and length of illness affecting ABI, and that this risk increased in patients aged ≥50 years and a history of diabetes-associated atherosclerosis.⁷ Complications such as uncontrolled blood sugar levels, i.e., random blood sugar level ≥ 200 mg/dL, and fasting blood sugar level ≥ 126 mg/dL occur in T2DM patients within an average period of 5–10 years.³² The low ABI is influenced by irregular consumption of anti-hyperglycemic drugs, irregular physical activity, irregular foot care, and irregularity in the T2DM diet.³³

This study shows that there was relationship between vitamin D and ABI. Vitamin D is associated with arterial atherosclerosis, which underlies an increased risk of CVD,^{34–36} and there is a strong association between vitamin D deficiency and the prevalence and severity of PAD,³⁷ however, other studies have demonstrated that serum levels of Vitamin D are not associated with arterial stiffness or PAD.³⁶ Previous studies have reported that vitamin D has a preventive role in patients with CVD.³⁹

This vitamin inhibits the renin–angiotensin–aldosterone system and modulates macrophage activity and cytokine production.³⁵ T2DM and vascular inflammation have become risk markers and even risk factors for atherothrombotic disease, including PAD. T2DM increases the process of atheroma formation. There is an increase in histamine levels in plasma and cells in patients with T2DM and PAD, which can lead to an increased endothelial permeability.⁴⁰ The next process is the migration of T-lymphocytes into the intima and the increase in the secretion and the activation of cytokines. Monocytes/macrophages ingest oxidized LDL molecules and turn them into foam cells, where the accumulation of these cells will form fatty streaks, which are the precursors of atheroma. Atheroma plaque will become unstable because endothelial cells in patients with T2DM secrete cytokines that inhibit collagen production by smooth muscle cells of the blood vessel. Metalloproteinases are also released by these inflammatory cells, which can destroy the collagen fibrous cap plaque atheroma, increasing the tendency for plaque rupture and thrombus formation.¹⁶ Systemic inflammation has also been evident to increase insulin resistance. T2DM is an inflammatory condition, and vitamin D may reduce insulin resistance by reducing the risk of inflammation.

There is an association between low vitamin D levels and T2DM, and impaired glucose tolerance.⁴¹ In populations with vitamin D deficiency and impaired glucose tolerance and T2DM, vitamin D supplementation can improve insulin secretion, glucose tolerance, and decrease HbA1c levels. The provision of vitamin D supplementation in healthy adults with this deficiency has shown to improve insulin sensitivity by 60%, which is better than rosiglitazone and other metformin therapy.⁴²

The abnormalities in the function of endothelial cells and vascular smooth muscle and the tendency to thrombosis are affected by atherosclerosis and its complications. Endothelial cells can regulate blood vessel function and structure because of the strategic anatomical position between the blood vessel walls and blood flow. Under normal circumstances, many active substances are synthesized and released by endothelial cells to maintain blood vessel homeostasis and to regulate blood flow and nutrients to the tissues while preventing thrombosis and leukocyte diapedesis.⁴³

Individuals with low serum vitamin D levels have an increased risk of dyslipidemia, insulin resistance, and T2DM. The effect of vitamin D on the improvement of T2DM can be directly obtained through insulin action. Vitamin D enhances insulin response to glucose transport by stimulating insulin receptor expression in peripheral tissues. Moreover, vitamin D improves the level and the integrity of lamellae in the aortic medium tunica and prevents fragmentation of the aortic elastic fibers. Vitamin D supplementation in adult patients with T2DM significantly improves lipid profiles. Therefore, it can be concluded that fat metabolism disorders are caused by vitamin D deficiency.⁴⁴

The limitation of this study was that it did not distinguish patients with a history of smoking from non-smoking individuals. The results of other studies also say that a history of or smoking affects blood vessels because it causes atherosclerosis in blood vessels that contributing significantly to the ABI value, and smoking can significantly increase DM patients experiencing diabetic peripheral neuropathy.⁴⁵

Conclusions

Early detection of macrovascular complications is vital to prevent morbidity and mortality in T2DM patients. ABI can be used for the early detection of macrovascular complications. Besides being simple and non-invasive, the ABI is also entirely accurate for detecting macrovascular complications in T2DM patients. The results demonstrated that there was a correlation between the ABI value and the average LDL-C level, triglycerides, and vitamin D.

Data availability

Underlying data

Figshare: Laboratory Result of type 2 DM Patients, <https://doi.org/10.6084/m9.figshare.14915724.v1>.⁴⁶

This project contains the following underlying data:

- Data file (physical examination results, patient characteristics, and laboratory results of patients (BGL, HbA1c, Total cholesterol, LDL-C, HDL-C, TG, Vitamin D))

Data are available under the terms of the [Creative Commons Zero “No rights reserved” data waiver](#) (CC0 1.0 Public domain dedication).

References

1. Silva EFF, Ferreira CMM, de Pinho L: **Risk factors and complications in type 2 diabetes outpatients.** *Rev. Assoc. Médica Bras.* 2017 Jul; **63**(7): 621–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
2. Jaiswal M, et al.: **Peripheral neuropathy in adolescents and young adults with type 1 and type 2 diabetes from the SEARCH for Diabetes in Youth follow-up cohort: a pilot study.** *Diabetes Care.* 2013 Dec 1; **36**(12): 3903–3908.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. Lin JS, Evans CV, Johnson E, et al.: **Nontraditional risk factors in cardiovascular disease risk assessment: updated evidence report and systematic review for the US Preventive Services Task Force.** *Jama.* 2018 Jul 17; **320**(3): 281–297.
[PubMed Abstract](#) | [Publisher Full Text](#)
4. Sigvant B, Lundin F, Wahlberg E: **The risk of disease progression in peripheral arterial disease is higher than expected: a meta-analysis of mortality and disease progression in peripheral arterial disease.** *Eur. J. Vasc. Endovasc. Surg.* 2016 Mar 1; **51**(3): 395–403.
[PubMed Abstract](#) | [Publisher Full Text](#)
5. Le Bivic L, et al.: **The intrinsic prognostic value of the ankle-brachial index is independent from its mode of calculation.** *Vasc. Med.* 2019 Feb; **24**(1): 23–31.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Li G, et al.: **The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study.** *Lancet.* 2008 May 24; **371**(9626): 1783–1789.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Park SY, et al.: **Effects of foot complications in patients with Type 2 diabetes mellitus on public healthcare: An analysis based on the Korea National Diabetes Program Cohort.** *J. Diabetes Complications.* 2017 Feb 1; **31**(2): 375–380.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. Alves-Cabrato L, et al.: **Levels of ankle-brachial index and the risk of diabetes mellitus complications.** *BMJ Open Diabetes Res. Care.* 2020 Mar 1; **8**(1): e000977.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. McClary KN, Index PMAB: **Ankle Brachial Index.** 2020 May 21. *StatPearls [Internet].* Treasure Island (FL): StatPearls Publishing; 2020 Jan.
[PubMed Abstract](#)
10. Fosgate GT: **Practical sample size calculations for surveillance and diagnostic investigations.** *J. Vet. Diagn. Investig.* 2009 Jan; **21**(1): 3–14.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Aboyans V, Criqui MH, Abraham P, et al.: **Measurement and interpretation of the ankle-brachial index: a scientific statement from the.** *J. Am. Heart Assoc.* 2012 Dec 11; **126**(24): 2890–2909.
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Aerden D, et al.: **The ankle-brachial index and the diabetic foot: a troublesome marriage.** *Ann. Vasc. Surg.* 2011 Aug 1; **25**(6): 770–777.
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Robinet P, Wang Z, Hazen SL, et al.: **A simple and sensitive enzymatic method for cholesterol quantification in macrophages and foam cells.** *J Lipid Res.* 2010 Nov 1; **51**(11): 3364–3369.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. Penumarthi S, Penmetsa GS, Mannem S: **Assessment of serum levels of triglycerides, total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol in periodontitis patients.** *J. Indian Soc. Periodontol.* 2013 Jan; **17**(1): 30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. WHO: **Body mass index - BMI.**
[Reference Source](#)
16. Moyer VA: **Screening for peripheral artery disease and cardiovascular disease risk assessment with the ankle-brachial index in adults: US Preventive Services Task Force recommendation statement.** *Ann. Intern. Med.* 2013 Sep 3; **159**(5): 342–348.
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Reis de Matos M, et al.: **Distal Symmetric and Cardiovascular Autonomic Neuropathies in Brazilian Individuals with Type 2 Diabetes Followed in a Primary Health Care Unit: A Cross-Sectional Study.** *Int. J. Environ. Res. Public Health.* 2020 Jan; **17**(9): 3232.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Zilliox LA, Ruby SK, Singh S, et al.: **Clinical neuropathy scales in neuropathy associated with impaired glucose tolerance.** *J. Diabetes Complications.* 2015 Apr 1; **29**(3): 372–377.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Hiramoto JS, Katz R, Weisman S, et al.: **Gender-specific risk factors for peripheral artery disease in a voluntary screening population.** *J. Am. Heart Assoc.* 2014 Mar 13; **3**(2): e000651.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Sheng B, Truong K, Spittler H, et al.: **The long-term effects of bariatric surgery on type 2 diabetes remission, microvascular and macrovascular complications, and mortality: a systematic review and meta-analysis.** *Obes. Surg.* 2017 Oct; **27**(10): 2724–2732.
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Sayin S, Kutlu R, Koçak A: **The relationship between atherogenic index of plasma and major risk factors of cardiovascular disease in obese and non-obese individuals.** *Eur. Res. J.* 2019; **5**(4): 678–685.
[Publisher Full Text](#)
22. Wu L, Parhofer KG: **Diabetic dyslipidemia.** *Metabolism.* 2014 Dec 1; **63**(12): 1469–1479.
[PubMed Abstract](#) | [Publisher Full Text](#)
23. Tucker WD, Arora Y, Mahajan K: **Anatomy, Blood Vessels.** *StatPearls [Internet].* 2020 Jan.
[Reference Source](#)
24. Heriansyah T, Wihastuti TA, Sargowo D, et al.: **Reduction of histopathological images through a decrease in H₂O₂ levels in diabetic rats with polysaccharide peptides.** *Biomarkers Genomic Med.* 2015 Mar 1; **7**(1): 31–7.
[Publisher Full Text](#)
25. Arca M, Montali A, Valiante S, et al.: **Usefulness of atherogenic dyslipidemia for predicting cardiovascular risk in patients with angiographically defined coronary artery disease.** *Am J Cardiol.* 2007; **100**(10): 1511–1516.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Amelia R, Sari MD, Virgayanti V, et al.: **Effect of duration of illness and lipid profile of type 2 Diabetes Mellitus patients on diabetic retinopathy.** *IOP Conf. Ser. Earth Environ. Sci.* 2021 Mar; **713**(1): 012058: 1.
27. Pop-Busui R, et al.: **Diabetic neuropathy: a position statement by the American Diabetes Association.** *Diabetes Care.* 2017; **40**(1): 136–154.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Amelia R, Sahbudin DKN, Yamamoto Z: **Stress level and self-concept among type 2 diabetes mellitus patients in Indonesia.** *Fam. Med. Prim. Care Rev.* 2020; **22**(2): 111–115.
[Publisher Full Text](#)
29. Amelia R, Harahap J, Lelo A, et al.: **Risk analysis for cardiovascular complication based on the atherogenic index of plasma of type 2 diabetes mellitus patients in Medan, Indonesia.** *Fam. Med. Prim. Care Rev.* 2020; **22**(3): 197–201.
[Publisher Full Text](#)
30. Wu Y, Ding Y, Tanaka Y, et al.: **Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention.** *Int. J. Med. Sci.* 2014; **11**(11): 1185.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Amelia R, Harahap J, Wahyuni AS, et al.: **Health status of elderly based on daily activities living, cholesterol and uric acid profile in Medan city.** *IOP Conference Series: Earth and Environmental Science.* 2018; **125**: 012175.
[Publisher Full Text](#)
32. Kumar A, Kumar A, Kumar H, et al.: **Prevalence of peripheral arterial disease & associated risk factors among type 2 diabetes mellitus patients attending diabetic health camp.** *Int J Med Res Internet.* 2018; **3**(2): 90–92.
[PubMed Abstract](#)
33. Shishehbor MH, et al.: **Critical limb ischemia: an expert statement.** *J. Am. Coll. Cardiol.* 2016 Nov 2002; **68**(18): 1.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Mitri J, et al.: **Plasma 25-hydroxyvitamin D and risk of metabolic syndrome: an ancillary analysis in the Diabetes Prevention Program.** *Eur. J. Clin. Nutr.* 2014 Mar; **68**(3): 376–383.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
35. Kang JY, Kim MK, Jung S, et al.: **The cross-sectional relationships of dietary and serum vitamin D with cardiometabolic risk factors: Metabolic components, subclinical atherosclerosis, and arterial stiffness.** *Nutrition.* 2016 Oct 1; **32**(10): 1048–1056.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Wang Z, et al.: **A systematic review and meta-analysis of tests to predict wound healing in diabetic foot.** *J. Vasc. Surg.* 2016 Feb 1; **63**(2): 295–365.
[PubMed Abstract](#) | [Publisher Full Text](#)

37. Ibhar AM, Arshed AQ: **Vitamin D and Cardiovascular Disease: Controversy Unresolved.** *J. Am. Coll. Cardiol.* 2017 Jul 4; **70**(1): 89–100.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. Wang L, *et al.*: **Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies.** *Circ. Cardiovasc. Qual. Outcomes.* 2012 Nov; **5**(6): 819–829.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. Nsengiyumva V, *et al.*: **The association of circulating 25-hydroxyvitamin D concentration with peripheral arterial disease: a meta-analysis of observational studies.** *Atherosclerosis.* 2015 Dec 1; **243**(2): 645–651.
[PubMed Abstract](#) | [Publisher Full Text](#)
40. Al Mheid I, Patel RS, Tangpricha V, *et al.*: **Vitamin D and cardiovascular disease: is the evidence solid.** *Eur. Heart J.* 2013 Dec 21; **34**(48): 3691–3698.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. Gregg EW, *et al.*: **Changes in diabetes-related complications in the United States, 1990–2010.** *N. Engl. J. Med.* 2014 Apr 17; **370**(16): 1514–1523.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Palomer X, González-Clemente JM, Blanco-Vaca F, *et al.*: **Role of vitamin D in the pathogenesis of type 2 diabetes mellitus.** *Diabetes Metab Syndr Obes.* 2008 Mar; **10**(3): 185–197.
[PubMed Abstract](#) | [Publisher Full Text](#)
43. Angellotti E, Pittas AG: **The role of vitamin D in the prevention of type 2 diabetes: to D or not to D?** *Endocrinology.* 2017 Jul 1; **158**(7): 2013–2021.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
44. Ducci K, *et al.*: **Ticagrelor versus clopidogrel in patients undergoing implantation of paclitaxel-eluting stent in the femoropopliteal district: A randomized pilot study using frequency-domain optical coherence tomography.** *Int. J. Cardiol.* 2020 Apr 1; **304**: 192–197.
[PubMed Abstract](#) | [Publisher Full Text](#)
45. Clair C, Cohen MJ, Eichler F, *et al.*: **The effect of cigarette smoking on diabetic peripheral neuropathy: a systematic review and meta-analysis.** *J. Gen. Intern. Med.* 2015 Aug; **30**(8): 1193–1203.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
46. Amelia R, Harahap J, Yunanda Y, *et al.*: **F1000-Data_Submit_F1000.xlsx.** *figshare. Dataset.* 2021.
[Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:  

Version 1

Reviewer Report 01 September 2021

<https://doi.org/10.5256/f1000research.58153.r91990>

© 2021 Kusananto H. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Hari Kusananto 

Department of Family and Community Medicine, Faculty of Medicine, Public Health and Nursing, Gadjah Mada University, Yogyakarta, Indonesia

This study is simple yet very powerful in advocating the use of Ankle Brachial Index as a risk measurement for peripheral arterial disease as a manifestation of macrovascular problem. The predictive capability of ABI to measure the risk for peripheral arterial disease is also consistent with the level of LDL-cholesterol and triglycerides known to be risk factors for cardiovascular diseases. Of particular interest, which should be emphasized in the discussion is concerning the positive association between the level of vitamin D and the level of peripheral arterial disease. This is a very important finding now when many people consume high dose of vitamin D to prevent severe COVID-19. Evidence-based explanation of the negative effect of higher level of vitamin D need some more elaboration.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Partly

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: My areas of research is epidemiology as applied to family medicine

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 31 August 2021

<https://doi.org/10.5256/f1000research.58153.r91992>

© 2021 Rohin M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The author(s) is/are employees of the US Government and therefore domestic copyright protection in USA does not apply to this work. The work may be protected under the copyright laws of other jurisdictions when used in those jurisdictions.



Mohd Adzim Khalili Rohin 

School of Nutrition and Dietetics, Faculty of Health Sciences, Sultan Zainal Abidin University, Kuala Terengganu, Malaysia

- The manuscripts could be improved if the authors include detailed information in methods with sufficient data and supporting evidence in results and discussion sections.
- The introduction needs to be justified, with limited evidence to show the magnitude of the problem.
- The conclusion could be more concise and better worded study implications.
- Language-wise is good.
- Limited references were used in supporting the findings. See Silva *et al.* (2017[ref 1]), Angellotti *et al.* (2017²) and Palomer *et al.* (2008³).

References

1. Silva EFF, Ferreira CMM, Pinho L: Risk factors and complications in type 2 diabetes outpatients. *Rev Assoc Med Bras (1992)*. 2017; **63** (7): 621-627 [PubMed Abstract](#) | [Publisher Full Text](#)
2. Angellotti E, Pittas A: The Role of Vitamin D in the Prevention of Type 2 Diabetes: To D or Not to D?. *Endocrinology*. 2017; **158** (7): 2013-2021 [Publisher Full Text](#)
3. Palomer X, González-Clemente JM, Blanco-Vaca F, Mauricio D: Role of vitamin D in the pathogenesis of type 2 diabetes mellitus. *Diabetes Obes Metab*. 2008; **10** (3): 185-97 [PubMed Abstract](#) | [Publisher Full Text](#)

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Community Nutrition, Functional Foods & Nutraceuticals

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research